

Prescribing Clinical Network

Policy Statement	Anticholinergics for the management of over active bladder (OAB) in men
Policy No:	PCN 289- 2017
Date of Issue	December - 2017
Review Date:	December - 2020 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i>
<p>Recommendations:</p> <p>The PCN recommends the following medicines as treatment options for the management of overactive bladder in men and has assigned the following traffic light status to each treatment option as follows</p> <p>GREEN 1st line</p> <ul style="list-style-type: none"> Oxybutinin (immediate release) OR Tolterodine (immediate release) <p>Alternative 1st line: (if ONCE daily preparation is required)</p> <ul style="list-style-type: none"> Trospium (modified release) OR Darifenacin (modified release) OR Oxybutynin transdermal patch for patients unable to take oral medications <p>GREEN 2nd line</p> <ul style="list-style-type: none"> Fesoterodine OR Trospium (immediate release) OR Tolterodine (modified release) OR Mirabegron If above treatments contraindicated. not tolerated or not effective: <p>The PCN does not recommend the following drugs as treatment options for the management of overactive bladder in men and has assigned the following traffic light status to each treatment option as follows</p> <ul style="list-style-type: none"> Propiverine (immediate release & modified release) – BLACK There are other more cost effective treatment options are available Oxybutynin modified release –BLACK There are other more cost effective treatment options are available Solifenacin – BLACK There are other more cost effective options available. Flavoxate – BLACK Not discussed in NICE clinical knowledge summaries <p>Patients whose treatment with the treatments above were initiated by the NHS before this recommendation was made, must be reviewed by their NHS consultant but should be able to continue treatment until, the patient and their NHS consultant consider it appropriate to stop.</p>	
<p>Key Considerations:</p> <ul style="list-style-type: none"> CG97: Lower urinary tract symptoms in men -: management https://www.nice.org.uk/guidance/cg97/resources/lower-urinary-tract-symptoms-in-men-management-pdf-975754394053 Oxybutinin & Tolterodine are considered more cost effective options and therefore are considered 1st line for LUTS in men 	

Date taken to Prescribing Clinical Network	6 th December 2017
Agreed by PCN members	26th March 2018

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG

F E N V A L